Percutaneous administration of allogeneic bone-forming cells for the treatment of delayed unions of fractures: a pilot study.
Allogeneic
Bone marrow Mesenchymal stem cells
Cell therapy
Delayed union
Fracture
Long bone
Treatment
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
26 06 2021
26 06 2021
Historique:
received:
30
12
2020
accepted:
06
06
2021
entrez:
27
6
2021
pubmed:
28
6
2021
medline:
13
7
2021
Statut:
epublish
Résumé
Overall, 5-10% of fractures result in delayed unions or non-unions, causing major disabilities and a huge socioeconomic burden. Since rescue surgery with autologous bone grafts can cause additional challenges, alternative treatment options have been developed to stimulate a deficient healing process. This study assessed the technical feasibility, safety and preliminary efficacy of local percutaneous implantation of allogeneic bone-forming cells in delayed unions of long bone fractures. In this phase I/IIA open-label pilot trial, 22 adult patients with non-infected delayed unions of long bone fractures, which failed to consolidate after 3 to 7 months, received a percutaneous implantation of allogeneic bone-forming cells derived from bone marrow mesenchymal stem cells (ALLOB; Bone Therapeutics) into the fracture site (50 × 10 During the 6-month follow-up, three serious treatment-emergent adverse events were reported in two patients, of which two were considered as possibly treatment-related. None of the 21 patients in the per-protocol efficacy population needed rescue surgery within 6 months, but 2/21 (9.5%) patients had rescue surgery within 30 months post-treatment. At 6 months post-treatment, an improvement of at least 2 points in TUS was reached in 76.2% of patients, the GDE score improved by a mean of 48%, and pain at palpation at the fracture site was reduced by an average of 61% compared to baseline. The proportion of blood samples containing donor-specific anti-HLA antibodies increased from 8/22 (36.4%) before treatment to 13/22 (59.1%) at 6 months post-treatment, but no treatment-mediated allogeneic immune reactions were observed. This pilot study showed that the percutaneous implantation of allogeneic bone-forming cells was technically feasible and well tolerated in patients with delayed unions of long bone fractures. Preliminary efficacy evidence is supporting the further development of this treatment. NCT02020590 . Registered on 25 December 2013. ALLOB-DU1, A pilot Phase I/IIa, multicentre, open proof-of-concept study on the efficacy and safetyof allogeneic osteoblastic cells (ALLOB®) implantation in non-infected delayed-union fractures.
Sections du résumé
BACKGROUND
Overall, 5-10% of fractures result in delayed unions or non-unions, causing major disabilities and a huge socioeconomic burden. Since rescue surgery with autologous bone grafts can cause additional challenges, alternative treatment options have been developed to stimulate a deficient healing process. This study assessed the technical feasibility, safety and preliminary efficacy of local percutaneous implantation of allogeneic bone-forming cells in delayed unions of long bone fractures.
METHODS
In this phase I/IIA open-label pilot trial, 22 adult patients with non-infected delayed unions of long bone fractures, which failed to consolidate after 3 to 7 months, received a percutaneous implantation of allogeneic bone-forming cells derived from bone marrow mesenchymal stem cells (ALLOB; Bone Therapeutics) into the fracture site (50 × 10
RESULTS
During the 6-month follow-up, three serious treatment-emergent adverse events were reported in two patients, of which two were considered as possibly treatment-related. None of the 21 patients in the per-protocol efficacy population needed rescue surgery within 6 months, but 2/21 (9.5%) patients had rescue surgery within 30 months post-treatment. At 6 months post-treatment, an improvement of at least 2 points in TUS was reached in 76.2% of patients, the GDE score improved by a mean of 48%, and pain at palpation at the fracture site was reduced by an average of 61% compared to baseline. The proportion of blood samples containing donor-specific anti-HLA antibodies increased from 8/22 (36.4%) before treatment to 13/22 (59.1%) at 6 months post-treatment, but no treatment-mediated allogeneic immune reactions were observed.
CONCLUSION
This pilot study showed that the percutaneous implantation of allogeneic bone-forming cells was technically feasible and well tolerated in patients with delayed unions of long bone fractures. Preliminary efficacy evidence is supporting the further development of this treatment.
TRIAL REGISTRATION
NCT02020590 . Registered on 25 December 2013. ALLOB-DU1, A pilot Phase I/IIa, multicentre, open proof-of-concept study on the efficacy and safetyof allogeneic osteoblastic cells (ALLOB®) implantation in non-infected delayed-union fractures.
Identifiants
pubmed: 34174963
doi: 10.1186/s13287-021-02432-4
pii: 10.1186/s13287-021-02432-4
pmc: PMC8235864
doi:
Banques de données
ClinicalTrials.gov
['NCT02020590']
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
363Références
Rev Bras Ortop. 2017 Dec 29;53(6):668-673
pubmed: 30377598
Int J Radiat Oncol Biol Phys. 1980 Mar;6(3):371-4
pubmed: 7390914
Transfusion. 2009 Sep;49(9):1825-35
pubmed: 19453983
Regen Med. 2015;10(3):305-15
pubmed: 25933239
Eur J Radiol. 2018 Jan;98:36-40
pubmed: 29279168
J Bone Joint Surg Am. 2005 Jul;87(7):1430-7
pubmed: 15995108
Biochem Biophys Res Commun. 2007 Mar 9;354(2):453-8
pubmed: 17239347
Transplantation. 2013 Jan 15;95(1):19-47
pubmed: 23238534
Clin Orthop Relat Res. 2000 Feb;(371):10-27
pubmed: 10693546
J Orthop Traumatol. 2019 Apr 11;20(1):21
pubmed: 30976944
J Orthop Res. 2017 Feb;35(2):213-223
pubmed: 27743449
Stem Cell Res Ther. 2017 Dec 22;8(1):288
pubmed: 29273086
J Bone Joint Surg Am. 2008 Feb;90 Suppl 1:62-7
pubmed: 18292359
J Orthop Trauma. 2015 Nov;29(11):516-20
pubmed: 26165265
Curr Pharm Des. 2013;19(13):2459-73
pubmed: 23278600
Indian J Orthop. 2007 Jan;41(1):67-71
pubmed: 21124686
Transplantation. 2018 Jan;102(1S Suppl 1):S1-S6
pubmed: 29266056
Injury. 2007 Sep;38 Suppl 4:S3-6
pubmed: 18224731
Biochem Biophys Res Commun. 2012 Oct 5;426(4):475-9
pubmed: 22960177
Int Orthop. 2013 Dec;37(12):2491-8
pubmed: 23948983
JAMA Surg. 2016 Nov 16;151(11):e162775
pubmed: 27603155
Transfusion. 2010 Jun;50(6):1328-34
pubmed: 20070615
World J Orthop. 2015 Sep 18;6(8):623-8
pubmed: 26396938
Bioact Mater. 2017 Jun 07;2(4):224-247
pubmed: 29744432
Injury. 2009 Dec;40 Suppl 3:S50-3
pubmed: 20082792
Biomaterials. 2019 Mar;196:100-108
pubmed: 29598897
BMC Musculoskelet Disord. 2009 Feb 12;10:20
pubmed: 19216734
Clin Orthop Relat Res. 1995 Apr;(313):8-18
pubmed: 7641502
Front Bioeng Biotechnol. 2018 Jul 31;6:105
pubmed: 30109228
Cells Tissues Organs. 2017;204(2):59-83
pubmed: 28647733
Int Orthop. 2014 Sep;38(9):1855-60
pubmed: 24658874
Curr Osteoporos Rep. 2018 Apr;16(2):155-168
pubmed: 29536393
Int Orthop. 2018 Feb;42(2):247-258
pubmed: 29273837
Nat Rev Rheumatol. 2015 Jan;11(1):45-54
pubmed: 25266456
Cochrane Database Syst Rev. 2011 Apr 13;(4):CD008471
pubmed: 21491410
JB JS Open Access. 2018 Oct 30;3(4):e0012
pubmed: 30882051
Bone. 2015 Jan;70:93-101
pubmed: 25093266
Lancet. 2016 Sep 24;388(10051):1281-90
pubmed: 27477896
Eur J Radiol. 2019 Sep;118:181-186
pubmed: 31439239
Bone Joint Res. 2013 Jun 14;2(6):102-11
pubmed: 23836474
J Bone Joint Surg Am. 2008 Sep;90(9):1862-8
pubmed: 18762645
Semin Cell Dev Biol. 2008 Oct;19(5):459-66
pubmed: 18692584
Acta Orthop. 2017 Aug;88(4):434-439
pubmed: 28508682
Bone Joint Res. 2019 Aug 2;8(7):304-312
pubmed: 31463038
Biomed Mater Eng. 2015;25(1 Suppl):187-97
pubmed: 25538069
J Mater Sci Mater Med. 2015 Nov;26(11):254
pubmed: 26449444
Calcif Tissue Int. 2008 Mar;82(3):238-47
pubmed: 18305886
J Cell Mol Med. 2015 Apr;19(4):685-713
pubmed: 25726940
Stem Cells Int. 2013;2013:312501
pubmed: 23766767
Front Immunol. 2017 Nov 24;8:1626
pubmed: 29225601